A PHASE 2 STUDY OF RETIFANLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC MERKEL CELL CARCINOMA (MCC) (POD1UM-201)

被引：16

作者：

Grignani, Giovanni ^{[1
]}

Rutkowski, Piotr ^{[2
]}

Lebbe, Celeste ^{[3
]}

Prinzi, Natalie ^{[4
]}

Grob, Jean-jaques ^{[5
]}

Tanda, Enrica Teresa ^{[6
]}

Guida, Michele ^{[7
]}

Burgess, Melissa ^{[8
]}

Pulini, Jennifer ^{[9
]}

Shankar, Sadhna ^{[9
]}

Tian, Chuan ^{[9
]}

Bhatia, Shailender ^{[10
]}

机构：

[1] FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy

[2] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[3] Univ Paris, Hop St Louis, AP HP, Dept Dermatol & CIC, Paris, France

[4] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[5] Aix Marseille Univ, AP HM Timone, Marseille, France

[6] IRCCS Osped Policlin San Martino, Skin Canc Unit, Genoa, Italy

[7] IRCCS Ist Tumori Giovanni Paolo II, Unit Melanoma & Rare Tumors, Bari, Italy

[8] UPMC Canc Ctr, Pittsburgh, PA USA

[9] Incyte Corp, Ambler, PA USA

[10] Univ Washington, Seattle, WA 98195 USA

来源：

关键词：

D O I：

10.1136/jitc-2021-SITC2021.545

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

545

引用

页码：A574 / A575

页数：2